Screener
CRISPR Therapeutics CRSP Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's asset turnover?
- CRISPR Therapeutics (CRSP) reported asset turnover of 0× in Q1 2026.
- How has CRISPR Therapeutics's asset turnover changed year-over-year?
- CRISPR Therapeutics's asset turnover decreased by 89.6% year-over-year, from 0× to 0×.
- What is the long-term trend for CRISPR Therapeutics's asset turnover?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's asset turnover has grown at a 26.2% compound annual growth rate (CAGR), from 0× to 0×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.
Ask your AI about CRISPR Therapeutics's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude